Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stockEmcure Pharmaceuticals Ltd (EMCURE) is currently trading at 1,734.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops and markets a broad range of pharmaceutical products worldwide, covering major therapeutic areas. It is strongly positioned in acute and chronic segments, such as gynecology, cardiovascular, oncology, and biologics. Emcure has entered into a notable partnership with Novo Nordisk to introduce an exclusive semaglutide drug, a major step in its biotechnology endeavors. This collaboration is expected to drive significant growth and visibility in the innovative drug market. The company reported a strong financial performance for Q3 FY26, with a 20.4% increase in revenue year-over-year and a profit of INR 231 crores, reflecting robust execution of its strategy and growth plans. With an expansive portfolio in both chemistry-driven products and biologics, Emcure focuses heavily on innovation and differentiated product offerings, including biosimilars and specialty products. Emcure's strategic alliances, such as those with Novo Nordisk and Sanofi, highlight its approach to leveraging partnerships to expand its therapeutic reach and enhance its competitive edge in chronic and biotech markets.
Over the past 52 weeks, Emcure Pharmaceuticals Ltd has traded between a low of ₹1,230.00 and a high of ₹1,830.35. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Emcure Pharmaceuticals Ltd has a market capitalization of approximately 31,912.12. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Emcure Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 31,912.12 Cr, Emcure Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Emcure Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Emcure Pharmaceuticals Ltd is 34.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Kotak Mahindra Mutual Fund bought 36 lakh shares, or 1.89% stake, in Emcure Pharmaceuticals via June 9 transactions.
The final issue price was ₹1,008 per share, and the stock listed at ₹1,325.05 on both NSE and BSE.
Emcure said it in-licensed Lenacapavir from Gilead Life Sciences for India and emerging markets, calling it a major development that strengthens its ARV portfolio.
The decline was attributed to profit booking after the earnings announcement, even though the company reported higher profit and revenue.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Emcure Pharmaceuticals is an Indian pharmaceutical company that develops and markets a broad range of pharmaceutical products worldwide, covering major therapeutic areas. It is strongly positioned in acute and chronic segments, such as gynecology, cardiovascular, oncology, and biologics.
Emcure has entered into a notable partnership with Novo Nordisk to introduce an exclusive semaglutide drug, a major step in its biotechnology endeavors. This collaboration is expected to drive significant growth and visibility in the innovative drug market.
The company reported a strong financial performance for Q3 FY26, with a 20.4% increase in revenue year-over-year and a profit of INR 231 crores, reflecting robust execution of its strategy and growth plans.
With an expansive portfolio in both chemistry-driven products and biologics, Emcure focuses heavily on innovation and differentiated product offerings, including biosimilars and specialty products.
Emcure's strategic alliances, such as those with Novo Nordisk and Sanofi, highlight its approach to leveraging partnerships to expand its therapeutic reach and enhance its competitive edge in chronic and biotech markets.
Pharmaceuticals & Biotechnology
Pharmaceuticals
31,912 Cr
Low Risk
34.5
34.1
1.5
6.5
1,830.35
1,230.00
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
3
Neutral
9
Bullish
2
Bearish
3
Neutral
9
Bullish
34
Bearish
0
Neutral
0
Bullish
32
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2255.15 | 38,031 Cr | 37.02 | 3.67 | 0.87 | 9.92 | 14.02 | 8.21 | ||
2258.20 | 36,155 Cr | 50.96 | 8.69 | 0.98 | 17.06 | 22.99 | 14.28 | ||
2115.70 | 35,621 Cr | 34.38 | 15.71 | 2.71 | 45.69 | 61.23 | 23.96 | ||
1734.25 | 31,912 Cr | 34.52 | 6.45 | 0.21 | 18.67 | 21.76 | 9.79 | ||
1934.95 | 31,312 Cr | 147.01 | 6.34 | 0.00 | 5.75 | 7.39 | 2.31 | ||
3146.45 | 25,617 Cr | 71.91 | 15.49 | 0.08 | 21.54 | 28.77 | 17.96 | ||
1218.90 | 25,036 Cr | 71.75 | 10.08 | 0.00 | 14.05 | 18.23 | 9.62 | ||
| Median: 7 Co. | — | 2115.70 | 31,912 Cr | 50.96 | 8.69 | 0.21 | 17.06 | 21.76 | 9.79 |
Investor Presentation
Emcure filed an investor presentation under Regulation 30 (dated June 12, 2026) outlining FY26 performance: INR 9,204 Cr revenue (+16.6%), EBITDA INR 1,789 Cr (19.4%), Adj. PAT INR 1,008 Cr (10.9%), plus strategic deals and pipeline.
Investor Presentation
Emcure submitted its June 2026 investor presentation under Regulation 30, highlighting FY26 results: Revenue INR 9,204 Cr (+16.6%), EBITDA INR 1,789 Cr (19.4%), Adj. PAT INR 1,008 Cr (10.9%), and strategic in‑licensing/acquisitions.
